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Abstract
Background: Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/
recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS)
was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide
patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and
persistent/recurrent CTEPH.
Methods: We performed an open-label, uncontrolled, single-arm, early access study in which 300 adult patients
with inoperable or persistent/recurrent CTEPH received riociguat adjusted from 1 mg three times daily (tid) to a
maximum of 2.5 mg tid. Patients switching from unsatisfactory prior pulmonary arterial hypertension (PAH)-targeted
therapy (n = 84) underwent a washout period of at least 3 days before initiating riociguat. The primary aim was to
assess the safety and tolerability of riociguat, with World Health Organization functional class and 6-min walking
distance (6MWD) as exploratory efficacy endpoints.
Results: In total, 262 patients (87%) completed study treatment and entered the safety follow-up (median treatment
duration 47 weeks). Adverse events were reported in 273 patients (91%). The most frequently reported serious adverse
events were syncope (6%), right ventricular failure (3%), and pneumonia (2%). There were five deaths, none of which
was considered related to study medication. The safety and tolerability of riociguat was similar in patients switched
from other PAH-targeted therapies and those who were treatment naïve. In patients with data available, mean ±
standard deviation 6MWD had increased by 33 ± 42 m at Week 12 with no clinically relevant differences between the
switched and treatment-naïve subgroups.
Conclusions: Riociguat was well tolerated in patients with CTEPH who were treatment naïve, and in those who were
switched from other PAH-targeted therapies. No new safety signals were observed.
Trial registration: ClinicalTrials.org NCT01784562. Registered February 4, 2013.
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Background
Chronic thromboembolic pulmonary hypertension
(CTEPH) is a form of pulmonary hypertension (PH) that
results from obstruction of the pulmonary vasculature
by residual organized thrombi. This leads to increased
pulmonary vascular resistance (PVR), progressive PH,
and ultimately death due to right ventricular failure
[1–3]. Pulmonary endarterectomy (PEA), the gold-
standard treatment for CTEPH, can potentially cure
the condition [4, 5]. However, up to 40% of patients
with CTEPH are considered technically inoperable,
while up to 51% of patients develop persistent/recur-
rent PH after undergoing PEA [6–9].
Riociguat is a soluble guanylate cyclase (sGC) stimula-
tor [10] that is approved for the treatment of inoperable
and persistent/recurrent CTEPH. Riociguat has a dual
mode of action, sensitizing sGC to endogenous nitric
oxide (NO) by stabilizing NO–sGC binding, and directly
stimulating sGC via a different binding site, independ-
ently of NO. This restores the NO–sGC–cyclic guano-
sine monophosphate (cGMP) pathway and increases
generation of cGMP [10]. In the 16-week, randomized,
double-blinded Phase III CHEST-1 study, riociguat was
well tolerated and significantly improved a range of clin-
ical endpoints in patients with inoperable and persist-
ent/recurrent CTEPH, including 6-min walking distance
(6MWD), PVR, N-terminal pro-hormone of brain natri-
uretic protein, and World Health Organization func-
tional class (WHO FC) [11]. In an open-label extension,
CHEST-2, improvements in 6MWD and WHO FC per-
sisted at 2 years, with no new safety signals identified
[12, 13].
The CTEPH early access study (EAS) was initiated to
assess the safety and tolerability of riociguat using inclu-
sion and exclusion criteria similar to those in CHEST-1,
but adjusted to reflect more closely real-world clinical
practice. The CTEPH EAS also provided early access to
riociguat – after positive Phase III results and before
final approval – for patients with inoperable CTEPH or
persistent/recurrent PH after PEA who had an inad-
equate response to off-label treatments approved for
pulmonary arterial hypertension (PAH), and who could
not participate in another CTEPH trial.
Methods
Eligible participants were 18–80 years old, with CTEPH
that was deemed technically inoperable by an experi-
enced surgeon/physician or persistent/recurrent PH
after PEA, who were not satisfactorily treated and could
not participate in another CTEPH trial. Patients were ei-
ther treatment naïve or had previously received treat-
ment with phosphodiesterase type 5 (PDE5) inhibitors,
endothelin receptor antagonists (ERAs), or prostanoids.
The study was carried out in accordance with Good
Clinical Practice Guidelines and the Declaration of
Helsinki. The study protocol was approved by the ethics
committees of all participating centers and all patients
gave their written informed consent.
This was an open-label, uncontrolled, single-arm,
Phase IIIb long-term surveillance study (registered at
ClinicalTrials.gov: identifier NCT01784562). The study
consisted of three phases: an 8-week dose-adjustment
phase; a maintenance phase that continued until rioci-
guat was approved and commercially available in the pa-
tient’s respective country (except in the UK, where
participation was limited to 18 months); and a safety
follow-up phase, in which all patients who stopped study
medication – including those who completed the study
and transitioned to commercial riociguat – had a safety
follow-up visit 30 days after discontinuation. During the
dose-adjustment phase, riociguat dose was adjusted from
a starting dose of 1 mg three times daily (tid) to a max-
imum of 2.5 mg tid according to systolic blood pressure
and signs and symptoms of hypotension, as previously
reported [11]. In cases of poor tolerability, a dose of
0.5 mg tid was permitted.
Patients not previously reaching their treatment goals
(as judged by the investigator) with prior PAH-targeted
therapies (PDE5 inhibitors, ERAs, or prostanoids) were
switched to riociguat. All switched patients underwent a
mandatory washout period (minimum 3 days) before
initiating riociguat. Patients were permitted to initiate
concomitant treatment with ERAs or prostanoids during
the maintenance phase of the study (after the dose-
adjustment phase) if the investigator considered it a
medical requirement, but treatment with specific or
non-specific PDE5 inhibitors, or NO donors, was not
permitted.
The primary aim of the study was to assess the safety
and tolerability of riociguat. Syncope was pre-defined as
an adverse event (AE) of special interest in the study
protocol. Events of syncope were reported as serious ad-
verse events (SAEs) by the investigator and followed up
with a questionnaire. In addition, clinical efficacy was
assessed using WHO FC and optional assessment of
6MWD. Study visits were conducted every 2 weeks until
Week 8 (dose-adjustment phase), then at Week 12 and
at 12-week intervals thereafter (maintenance phase),
with a safety follow-up visit 30 days after discontinuation
for all patients who stopped study medication (safety
follow-up phase).
All variables were analyzed descriptively in this open-
label, non-comparative study. The statistical evaluation
was performed using the SAS software package (release
9.2; SAS Institute Inc., Cary, NC, USA). The full analysis
set included all patients who received at least one dose
of study drug. Data were also analyzed in the subgroup
of patients who switched from other PH medications to
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riociguat, defined as those who previously received an
ERA, prostanoid, and/or PDE5 inhibitor. Baseline was
defined as the last set of measurements taken before the
first dose of riociguat.
Results
In total, 300 patients, enrolled between March 2013 and
December 2015, received riociguat treatment in the
CTEPH EAS and were included in the full analysis set.
Study treatment was completed by 262 patients (87%)
(Fig. 1). Thirty-eight patients discontinued riociguat
treatment during either the dose-adjustment or mainten-
ance phase. The most frequent reason for discontinu-
ation was an AE (n = 14). A further four patients
discontinued during the safety follow-up phase, resulting
in 258 patients (86%) completing the entire study.
Baseline demographic and disease characteristics are
shown in Table 1; most patients were female (62%), in
WHO FC II/III (96%), and had inoperable CTEPH
(72%). The median treatment duration was 47 weeks
(range 0–121 weeks).
Of the 300 patients, 84 (28%) had switched to rioci-
guat from prior PAH-targeted therapies at the discretion
of the treating physician, with a median washout dur-
ation of 4 days (range 3–74 days). One patient had
stopped PAH-targeted medication 74 days prior to start-
ing treatment with riociguat, and was not taking PAH
medication at screening, so can be considered as an out-
lier. In total, 58 patients (19%) switched from PDE5 in-
hibitors (most frequently sildenafil [14%]) and 44
patients (15%) switched from ERAs (most frequently
bosentan [12%]; Table 2). In total, 24 patients (8%) were
switched from combination therapy to riociguat; the
most common combination therapy prior to switching
was a PDE5 inhibitor plus an ERA.
At Week 12 (the first visit after the dose-adjustment
phase), 237 of 263 available patients (90%) were receiv-
ing riociguat 2.5 mg tid, and no patients were receiving
riociguat 0.5 mg tid. During the study, 286 patients
(95%) started additional medication, most commonly
cardiac therapy (65%) and drugs for gastrointestinal
acid-related disorders (47%). PAH-targeted therapies
were newly started or restarted by 42 patients (14%), in-
cluding 18 patients (21%) from the switched subgroup
(n = 84) and 24 patients (11%) from the treatment-naïve
subgroup (n = 216). The majority of patients started/
restarted PAH-targeted therapies due to worsening
CTEPH. Thirty-six patients (12%) started ERAs during
the study, and six (2%) started prostacyclins. Four pa-
tients (1%) started PDE5 inhibitor therapy during the
study, of whom three discontinued riociguat on the same
day, and one patient received PDE5 inhibitors for 1 day
concomitantly with riociguat due to investigator error.
In the switched subgroup 17 patients (20%) started
ERAs, and one (1%) started prostacyclins during the
maintenance phase. Two patients (2%) restarted PDE5
inhibitors on the same day as discontinuing riociguat.
The most frequent reason for starting a new PAH-
targeted medication was worsening PH, as determined
by the investigator.
Fig. 1 Patient disposition. *Patients who discontinued treatment prematurely were to enter the safety follow-up phase
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AEs were reported in 273 patients (91%) treated with
riociguat (Table 3). The maximum severity of AEs
experienced by individual patients was mild for 90
patients (30%), moderate for 109 patients (36%), and se-
vere for 74 patients (25%). The most frequently reported
AEs were dyspepsia (20%), dizziness (19%), headache
(18%), and peripheral edema (18%) (Table 4). The most
frequently reported SAEs were syncope (n = 17; 6%),
right ventricular failure (n = 8; 3%), and pneumonia (n =
7; 2%).
During the washout phase between stopping prior
non-satisfactory PAH-targeted therapy and initiation of
riociguat (median duration 4 days, range 3–74 days), 11
of 84 patients (13%) in the switched subgroup experi-
enced AEs. Eight of these AEs were mild in severity, and
none was severe (Table 5). There were two SAEs during
the washout phase: one event of possible syncope which
started 3 days after discontinuing PDE5 inhibitor treat-
ment (sildenafil) and resolved the same day; and one
hospitalization resulting from septicemia which started
3 days after discontinuing ERA treatment (bosentan)
and resolved 6 days later.
Five deaths (2%) were reported during the study (one
case each of pleomorphic malignant fibrous histiocy-
toma, pneumonia, head injury, cardiac failure, and pul-
monary embolism) and one additional patient died
during the safety follow-up phase (due to cardiogenic
shock as a result of pneumonia and worsening chronic
heart failure). None of the deaths was considered by the
investigator to be related to study medication.
All events of syncope (n = 17, 6%; Table 4) were re-
ported as SAEs per definition; most were assessed as
mild or moderate in intensity, and none led to perman-
ent discontinuation of riociguat. Events of syncope were
considered drug related in four patients; in two cases,
the riociguat dose was unchanged, in one case the dose
was reduced, and in one case riociguat was interrupted
and later restarted. There was no association between
Table 1 Patient characteristics at baseline
Characteristic Full analysis set
(n = 300)
Switched patients
(n = 84)a
Treatment-naïve
patients (n = 216)
Sex, n (%)
Female 185 (62) 55 (65) 130 (60)
Male 115 (38) 29 (35) 86 (40)
Age (mean ± SD), years 63.9 ± 12.5 65.5 ± 11.6 63.3 ± 12.7
Type of CTEPH, n (%)
Inoperable 216 (72) 64 (76) 152 (70)
Persistent/recurrent 84 (28) 20 (24) 64 (30)
WHO FC, n (%)
I 5 (2) 0 5 (2)
II 112 (37) 31 (37) 81 (38)
III 175 (58) 51 (61) 124 (57)
IV 8 (3) 2 (2) 6 (3)
6MWD (mean ± SD), m 374 ± 117b 389 ± 87c 369 ± 125d
6MWD 6-min walking distance, CTEPH chronic thromboembolic pulmonary hypertension, ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5, SD
standard deviation, WHO FC World Health Organization functional class
aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat
bn = 213; last observed value prior to start of study treatment
cn = 52
dn = 161
Table 2 PAH-targeted therapy received prior to switching to
riociguat
Therapy, n (%) Full analysis set
(n = 300)
Any prior therapy 84 (28)
Endothelin receptor antagonists 44 (15)
Ambrisentan 8 (3)
Bosentan 36 (12)
PDE5 inhibitors 58 (19)
Sildenafil 42 (14)
Tadalafil 16 (5)
Prostacyclins and prostacyclin analogues 7 (2)
Beraprost 1 (<1)
Iloprost 6 (2)
Combination therapy 24 (8)
Double therapy 23 (8)
Triple therapy 1 (<1)
PAH pulmonary arterial hypertension, PDE5 phosphodiesterase type 5
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dose adjustment of riociguat and events of syncope. In-
deed, many events were associated with physical activity
or were orthostatic in nature. In the majority of the
cases there were no further episodes of syncope, or the
events resolved after treatment of a concurrent illness or
adjustment of concomitant medications.
All patients who experienced events of syncope or
pre-syncope had concomitant diseases, and were re-
ceiving concomitant medications during the study,
which may have increased the risk of an event. Fur-
thermore, seven patients (26%) had previous episodes
of syncope and three (11%) had previous episodes of
dizziness. In terms of concomitant diseases, 23 pa-
tients (85%) had respiratory disorders, 16 (59%) had
vascular disorders, and 14 (52%) had cardiac disor-
ders. The most common concomitant medications
were anticoagulants (n = 27, 100%), gastrointestinal
protective drugs for acid-related disorders (n = 20,
74%), and diuretics (n = 18, 67%). Four patients (15%)
received concomitant antihypertensive medications.
Dizziness was reported in 56 (19%) patients, eight (3%)
patients experienced falls, and one patient (<1%) experi-
enced orthostatic collapse. One patient had a fatal head
trauma following an accidental fall; the patient had four
previous episodes of falls, none of which was considered
to be related to syncope or pre-syncope by the investiga-
tor, and no hypotension was reported in this patient.
Thirty-six hypotension-related events were reported in
32 patients (11%; a rate of 12.4 events per 100 patient-
years), including 19 mild, 12 moderate, and five severe
events. Nineteen events of hypotension occurred during
the dose-adjustment phase, which led to dose reduction
in four patients and drug withdrawal in one patient.
Hypotension was classed as an SAE in four patients
(1%), as the events required or prolonged hospitalization;
riociguat treatment was interrupted in one patient and
remained unchanged in the other three patients. All
SAEs of hypotension were considered severe and had re-
solved by the end of the study.
Hemoptysis was reported in 11 patients (4%), of
whom four (1%) were classified as having serious
hemoptysis (moderate, n = 3; severe, n = 1). Two
SAEs of hemoptysis were considered study drug re-
lated; in one case, no changes were made to the dose
of riociguat and in the other case riociguat was with-
drawn. All SAEs of hemoptysis had resolved by the
end of the study.
Overall, the safety of riociguat was similar in patients
who were switched from other PAH-targeted therapies
and those who were treatment naïve (Table 3).
Four patients (1%) underwent balloon pulmonary
angioplasty during the study, including one pre-
planned procedure. Three of the procedures, consist-
ing of between two and four interventions, were con-
sidered successful by the investigators, whereas in one
patient stress cardiomyopathy was observed, which
had not resolved by the end of the study. The patient
Table 3 Summary of AEs during treatment with riociguat
AE, n (%) Full analysis set
(n = 300)
Switched patients
(n = 84)a
Treatment-naïve
patients
(n = 216)
Any AE 273 (91) 76 (90) 197 (91)
Drug-related AEs 178 (59) 53 (63) 125 (58)
Serious AEs 89 (30) 22 (26) 67 (31)
Drug-related serious AEs 19 (6) 4 (5) 15 (7)
AEs leading to discontinuation of study medication 14 (5) 5 (6) 9 (4)
Deaths 5 (2) 0 5 (2)
AE adverse event, PDE5 phosphodiesterase type 5, ERA endothelin receptor antagonist
aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat
Table 4 AEs occurring in ≥10% of patients and AEs of special
interest occurring during treatment with riociguat
Full analysis set
(n = 300)
Incidence per 100 patient-
years
AE, n (%)
Dyspepsia 60 (20) 27.5
Dizziness 56 (19) 26.0
Headache 54 (18) 29.4
Peripheral edema 54 (18) 23.0
Diarrhea 45 (15) 20.0
Nausea 43 (14) 18.8
Cough 38 (13) 16.6
Vomiting 34 (11) 16.6
Hypotension 29 (10) 12.4
Constipation 31 (10) 13.6
Gastroesophageal reflux
disease
31 (10) 12.8
Nasopharyngitis 31 (10) 14.7
AE of special interest, n (%)
Pre-syncope 10 (3) 4.1
Syncope 17 (6) 9.8
AE adverse event
McLaughlin et al. BMC Pulmonary Medicine  (2017) 17:216 Page 5 of 9
who experienced stress cardiomyopathy was in WHO
FC II at both baseline and Week 12, and had a con-
sistent 6MWD >500 m, indicating no serious
deterioration.
Assessment of 6MWD was optional during the
CTEPH EAS, and therefore data were not available for
all patients. The available data are summarized in
Table 6. At baseline, mean ± SD 6MWD was 374 ± 117
(n = 213), and switched patients had numerically higher
6MWD compared with treatment-naïve patients (389 ±
87 m versus 369 ± 125 m). The percentage of patients in
WHO FC I/II/III/IV at baseline was 2%/37%/58%/3%
(n = 300) (Table 7). In patients who had a 6MWD meas-
urement at Week 12, mean ± SD change from baseline
was +33 ± 42 m (n = 130; absolute value at Week 12 was
416 ± 111 m, n = 153) (Table 6). After 12 weeks of treat-
ment (n = 264), WHO FC had improved in 58 patients
(22%), remained stable in 193 (73%), and worsened in 13
(5%) (Table 7). Improvements in 6MWD and WHO FC
were seen in both treatment-naïve and switched patients
(Tables 6 and 7).
Discussion
The open-label, uncontrolled CTEPH EAS provided fur-
ther information on the safety and clinical efficacy of
riociguat in patients with CTEPH, and gave access to
riociguat for patients who could not participate in an-
other clinical trial. The results of this study were in
agreement with the results of the Phase III CHEST-1
study and the CHEST-2 long-term extension [11–13],
and showed that riociguat is well tolerated in patients
with CTEPH.
As riociguat is a vasodilator, potential side effects in-
clude hypotension and hypotension-related disorders.
The rate of hypotension in patients with CTEPH has
previously been shown to decrease with increasing rioci-
guat treatment duration. At the end of the 16-week
CHEST-1 trial, the rate of hypotension was 31.2 events
per 100 patient-years, while after 2 years of CHEST-2
(median treatment duration 116 weeks) the rate of
hypotension had fallen to 4.0 events per 100 patient-
years [13]. As the median treatment duration in the
CTEPH EAS (47 weeks) lies between the durations in
CHEST-1 and CHEST-2, the recorded rate of
hypotension of 12.4 events per 100 patient-years appears
to be in the expected range.
Syncope is a known symptom of PH, associated with
reduced central perfusion. Events of syncope, as an
outcome-related symptom of interest to treating physi-
cians, were recorded as AEs of special interest in the
CTEPH EAS, and were assessed using a targeted ques-
tionnaire. In the previous controlled study, CHEST-1,
syncope was not associated with riociguat treatment. In
agreement with this, the questionnaire and available in-
formation in the CTEPH EAS showed no direct associ-
ation between the administration of riociguat and
occurrence of syncope. Although the rate of syncope in
the CTEPH EAS (9.8 events per 100 patient-years) was
Table 5 Summary of AEs in switched patients during the
washout phase of the study
AE, n (%) Switched patients
(n = 84)a
Any AE 11 (13)
Maximum intensity of any AE
Mild 8 (10)
Moderate 3 (4)
Any serious AE 2 (2)
Deaths 0 (0)
AE adverse event, ERA endothelin receptor antagonist, PDE5
phosphodiesterase type 5
aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor,
and who stopped this treatment before starting riociguat
Table 6 Change from baseline in 6MWD (optional assessment)
Timepoint Full analysis set Switched patientsa Treatment-naïve patients
n Change from baseline
(mean ± SD), m
n Change from baseline
(mean ± SD), m
n Change from baseline
(mean ± SD), m
Dose-adjustment phase
Week 2 75 +20 ± 42 22 +8 ± 48 53 +25 ± 38
Week 4 77 +34 ± 39 19 +36 ± 31 58 +34 ± 42
Week 6 72 +41 ± 49 20 +30 ± 39 52 +45 ± 53
Week 8 93 +30 ± 70 21 +26 ± 47 72 +31 ± 76
Maintenance phase
Week 12 130 +33 ± 42 32 +28 ± 39 98 +34 ± 43
Week 24 105 +30 ± 63 20 +32 ± 45 85 +29 ± 67
Week 36 93 +32 ± 59 24 +37 ± 44 69 +31 ± 64
Week 48 62 +42 ± 60 13 +36 ± 68 49 +43 ± 59
6MWD 6-min walking distance, ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5, SD standard deviation
aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat
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higher than the rates of syncope observed in the rioci-
guat arm of CHEST-1 and the CHEST-2 long-term ex-
tension (7.8 events per 100 patient-years and 5.2 events
per 100 patient-years, respectively), it was lower than the
rate observed in the placebo arm of the CHEST-1 study
(15.1 events per 100 patient-years) [13]. Moreover, the
proportions of patients experiencing syncope with rioci-
guat in CHEST-1 and -2 and the CTEPH EAS (2%, 10%
and 6%, respectively) were lower than in the inter-
national CTEPH registry, in which 13.7% of patients ex-
perienced syncope [9]. Data on the rate of syncope in
CTEPH patients are lacking, and syncope has not been
investigated as an event of special interest in other trials
such as the BENEFiT study [14]. The results of the
CTEPH EAS suggest that syncope and pre-syncope may
occur in patients with CTEPH with many of the re-
ported cases associated with physical exertion or of
orthostatic nature, or in context with underlying condi-
tions or concomitant medications. However, it should
also be noted that there are many potential causes for
syncope in the relatively elderly patient population en-
rolled in this study (mean age 64 years versus 59 years
in the CHEST-1 study [11]).
Overall, we found that the safety profile of riociguat in
this study was consistent with that observed in CHEST-
1 and CHEST-2 [11–13], with the usual vasodilatory ef-
fects, and no new safety signals were reported. The
safety profile was also consistent with that seen in pa-
tients with PAH in the Phase III PATENT study in pa-
tients with PAH [15].
As the main aim of the CTEPH EAS was to assess the
safety and tolerability of riociguat, and 6MWD assess-
ments were therefore optional, only half of the patients
recorded 6MWD at Week 12. An improvement in
6MWD of +33 m was observed at Week 12, while the
improvement after 1 year was +37 ± 72 m (n = 43).
However, these results need to be interpreted with cau-
tion because of the exploratory nature of the efficacy as-
sessments in the CTEPH EAS.
Although riociguat is the only approved therapy for
inoperable and persistent/recurrent CTEPH, off-label
treatment with drugs approved for PAH, including
PDE5 inhibitors, ERAs, and prostanoids, is common
[9, 16–18]. In this study, 84 patients (28%) switched
to riociguat monotherapy from previous treatment
with PAH-approved therapies on which they had
shown an insufficient clinical response. Of these pa-
tients, 24 (8%) were previously receiving combination
therapy, including one patient on triple therapy.
While it should be noted that in order to minimize
risks to the patient this would not be the usual ap-
proach to changing treatment regimens in clinical
practice, the safety and tolerability of riociguat in pa-
tients who switched was similar to that in patients
who were treatment naïve, regardless of their previous
PAH-targeted treatment regimen. Furthermore, there
were no apparent safety issues associated with the
treatment-free washout period (median duration
4 days, range 3–74 days). Although 11 patients (13%)
experienced AEs during this phase, the majority of
the cases were mild (10%). In addition, there were no
relevant differences in change from baseline in
6MWD and WHO FC between patients in the
switched and treatment-naïve subgroups.
Baseline real-world data have been published from
national and international registries of patients with
CTEPH [7–9, 16–19], showing similar demographic
characteristics to those of patients in the CTEPH EAS
(mean age, 57–61 versus 64 years, respectively) [7, 8, 18,
19] and including 46–60% versus 62% female patients,
respectively [7–9, 16–19]. There were, however, differ-
ences in baseline exercise and functional capacity
Table 7 Change from baseline in WHO FC
Timepoint Full analysis set Switched patientsa Treatment-naïve patients
n Improved/stabilized/
worsened (%)
n Improved/stabilized/
worsened (%)
n Improved/stabilized/
worsened (%)
Dose-adjustment phase
Week 2 293 8/90/2 82 5/94/1 211 9/89/3
Week 4 292 13/84/2 81 12/86/1 211 14/83/3
Week 6 289 15/83/2 79 11/87/1 210 16/82/2
Week 8 284 19/79/2 78 17/82/1 206 20/78/2
Maintenance phase
Week 12 264 22/73/5 70 21/76/3 194 22/72/6
Week 24 208 25/70/5 52 17/79/4 156 28/67/5
Week 36 162 30/69/1 43 23/77/0 119 32/66/2
Week 48 114 29/69/2 28 21/79/0 86 31/66/2
ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5, WHO FC World Health Organization functional class
aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat
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between patients in the CTEPH EAS compared with
registries. For example, 39% of patients in the CTEPH
EAS were in WHO FC I or II at baseline compared with
9–23% of those in the registries [9, 16, 18]. Similarly,
mean 6MWD at baseline was higher for patients in the
CTEPH EAS compared with patients in the registries
(374 m versus 239–341 m) [7–9, 16–19]. In addition,
fewer patients in the CTEPH EAS were previously re-
ceiving PAH-targeted therapies compared with those en-
rolled in the registries (28% versus 29–90%). Baseline
demographic characteristics in the CTEPH EAS were
also similar to those in the CHEST-1 study (female pa-
tients 62% versus 66%, respectively), although disease se-
verity in terms of WHO FC I/II (39% versus 32%) and
6WMD (374 m versus 347 m) was slightly worse in the
CHEST-1 study [11]. Unlike patients in the CTEPH
EAS, however, patients in CHEST-1 were excluded if
they had received prior PH therapy within 3 months be-
fore study entry.
The limitations of the CTEPH EAS study, including
the open-label, non-comparative design, are common to
all long-term safety studies. In addition, the use of con-
comitant therapy in the study means that the safety and
efficacy findings cannot unequivocally be attributed to
riociguat. However, there was a relatively low rate of
new PAH-targeted concomitant therapies throughout
the study (14%). It should also be noted that assessment
of 6MWD in the CTEPH EAS was optional, leading to a
potential negative bias and relatively low patient
numbers. Nevertheless, open-label, non-comparative
studies such as the CTEPH EAS are important to bridge
the gap between Phase III studies and real-world data
from registries.
Conclusions
In conclusion, riociguat was well tolerated in patients
with CTEPH, with no new safety signals observed com-
pared with other riociguat trials. Furthermore, no rele-
vant differences in the safety profile were detected in
treatment-naïve patients and those switched from other
PAH-targeted therapies. Improvements in 6MWD and
WHO FC were also observed. The data in the CTEPH
EAS support the previous evidence for riociguat as a
long-term treatment option for patients with CTEPH.
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